/
MRNA
$71.07+$1.37 (+1.97%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$26.7B
397M shares
52-week range
$22.28 – $73.28
96% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
0.30%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-164.04
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $135.1M | $60.2M | $803.4M | $17.74B | $18.88B | $6.85B | $3.20B | $1.94B |
| Cost of revenue | $24.9M | $31.0M | $39.2M | $2.62B | $5.42B | $4.69B | $1.46B | $868.0M |
| Gross profit | $110.2M | $29.2M | $764.2M | $15.12B | $13.46B | $2.15B | $1.74B | $1.08B |
| Gross margin | 81.6% | 48.5% | 95.1% | 85.2% | 71.3% | 31.5% | 54.2% | 55.3% |
| R&D | $454.1M | $496.3M | $1.37B | $1.99B | $3.29B | $4.84B | $4.54B | $3.13B |
| Operating income | −$468.9M | −$545.7M | −$763.1M | $13.30B | $9.42B | −$4.24B | −$3.94B | −$3.07B |
| EBITDA | −$412.1M | −$477.1M | −$703.4M | $13.54B | $9.95B | −$3.28B | −$3.39B | −$2.55B |
| Net income | −$384.7M | −$514.0M | −$747.1M | $12.20B | $8.36B | −$4.71B | −$3.56B | −$2.82B |
| Net margin | -284.8% | -853.7% | -93.0% | 68.8% | 44.3% | -68.8% | -111.3% | -145.2% |
| EPS (diluted) | -1.17 | -1.55 | -1.96 | 28.29 | 20.10 | -12.34 | -9.27 | -7.26 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $2.1B | $-8.58 | $-9.76–$-7.21 | 17 |
| 2027 | $2.5B | $-4.69 | $-6.15–$-0.09 | 17 |
| 2028 | $3.2B | $-2.82 | $-5.93–$0.66 | 17 |
| 2029 | $5.2B | $0.21 | $0.16–$0.34 | 13 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Moderna, Inc. Common Stock
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
www.modernatx.com- Employees
- 4,700
- IPO / List date
- Dec 7, 2018
- HQ
- CAMBRIDGE, MA
Held by traders on TradeandTell
No one on the platform currently holds MRNA.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 881,200 | $44.8M |
| Bridgewater Associatesas of 2026-03-31 | 74,822 | $3.8M |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2017-08-03 | 1-for-10reverse |
| 2011-12-23 | 1-for-10reverse |
| 2010-07-22 | 1-for-4reverse |
Recent trades on TradeandTell
No one on the platform has traded MRNA yet.
